Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Intradermal DLX105 in Psoriasis
NCT01595997Phase 2Completed
- Sponsor
- Delenex Therapeutics
- Start
- Feb 2012
- Primary completion
- Aug 2012
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of DLX105 in Psoriasis vulgaris (PV), sponsored by Delenex Therapeutics. Started Feb 2012; status: completed.
02
Drugs
DLX105
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT01595997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01595997.